A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context
Summary: Background: CDK4/6 inhibitors (CDK4/6i) are used for management of hormone receptor-positive (HR+) metastatic breast cancer (MBC), and activation of the RAS/MAPK and PI3K/AKT signalling pathways has been implicated in resistance to these agents. Pathogenic NF1 mutations (pNF1m) dysregulate...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396425002725 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399028182155264 |
|---|---|
| author | Maxwell R. Lloyd Rosario Chica-Parrado Caroline M. Weipert Todd C. Knepper Emily L. Podany Fabiana Napolitano Dan Ye Chang-Ching Lin Yasuaki Uemoto Jiemin Liao Claire Wegrzyn Christine M. Walko Lianne Y. Ryan Jennifer C. Keenan Arielle J. Medford Shiyuan A. Liu Gerburg M. Wulf Katherine K. Clifton Cynthia X. Ma Hyo S. Han Nicole Zhang Leif W. Ellisen Aditya Bardia Carlos L. Arteaga Ariella B. Hanker Seth A. Wander |
| author_facet | Maxwell R. Lloyd Rosario Chica-Parrado Caroline M. Weipert Todd C. Knepper Emily L. Podany Fabiana Napolitano Dan Ye Chang-Ching Lin Yasuaki Uemoto Jiemin Liao Claire Wegrzyn Christine M. Walko Lianne Y. Ryan Jennifer C. Keenan Arielle J. Medford Shiyuan A. Liu Gerburg M. Wulf Katherine K. Clifton Cynthia X. Ma Hyo S. Han Nicole Zhang Leif W. Ellisen Aditya Bardia Carlos L. Arteaga Ariella B. Hanker Seth A. Wander |
| author_sort | Maxwell R. Lloyd |
| collection | DOAJ |
| description | Summary: Background: CDK4/6 inhibitors (CDK4/6i) are used for management of hormone receptor-positive (HR+) metastatic breast cancer (MBC), and activation of the RAS/MAPK and PI3K/AKT signalling pathways has been implicated in resistance to these agents. Pathogenic NF1 mutations (pNF1m) dysregulate RAS signalling, but NF1 has not been linked to CDK4/6i resistance. We analysed multi-institutional data, real-world evidence, and preclinical models to characterise the impact of pNF1m on CDK4/6i sensitivity. Methods: A retrospective cohort of patients with pNF1m tumours were identified from 4 institutions between 2/2015–5/2023 and evaluated for progression-free survival and intrinsic/acquired resistance on CDK4/6i. Real-world clinical-genomic data from GuardantINFORM between 6/2014 and 3/2023 was analysed for associations between pNF1m and time-to-next-treatment or overall survival following CDK4/6i, adjusted using propensity score weighting. We used CRISPR/Cas9 to delete NF1 in MCF7 and T47D breast cancer cells in vitro. NF1-knockout (NF1-KO) and -wild-type (WT) cells were analysed with respect to CDK4/6i sensitivity, MAPK and PI3K pathway activation, and sensitivity to MAPK and PI3K pathway inhibitors. In parallel, we assessed treatment response in a patient-derived organoid (PDO) harbouring NF1 loss, established from an HR+/HER2− breast tumor following progression on a CDK4/6i. Findings: Among 1962 multicentre patients, we identified 38 with HR+/HER2- MBC, pNF1m, and exposure to CDK4/6i. NF1-associated intrinsic or acquired resistance to CDK4/6i was observed in a majority of tumours, and in those with baseline pNF1m on first-line CDK4/6i, a median progression-free survival of 6.2 months was much less than expected in routine practice. Real-world weighted analysis of 1161 patients comparing 28 pNF1m to 1133 NF1 non-altered tumours demonstrated shorter time-to-next-treatment on CDK4/6i regimens (4.2 vs. 12.4 months, hazard ratio 3.14, 95% confidence interval 2.01–4.93) and overall survival (15.8 vs. 45.2 months, hazard ratio 2.04, 95% confidence interval 1.09–3.82). NF1-deleted cells exhibited reduced sensitivity to CDK4/6i with or without oestrogen suppression, which was accompanied by induction of both MAPK and PI3K pathways, the latter of which was exacerbated by CDK4/6i. Blockade of RAS or AKT, but not MEK or ERK, reversed CDK4/6i resistance mediated by NF1 loss in cell lines and the PDO. Interpretation: NF1 mutations are associated with shorter therapy duration on CDK4/6i in MBC. A causal link between NF1 loss and CDK4/6i resistance was supported by experiments in HR + breast cancer cells. NF1 deletion was accompanied by activation of ERK and AKT, and blockade of RAS or AKT combined with CDK4/6i was effective in NF1-deleted cells and an NF1-mutant PDO. Funding: Breast Cancer Research Foundation DRC-20-001, National Cancer Institute R01CA273246, National Institute of Health P30 CA142543, Susan G. Komen Breast Cancer Foundation SAB1800010, Department of Defence BC 210406, Mary Kay Ash Foundation International Postdoctoral Scholars in Cancer Research Fellowship. |
| format | Article |
| id | doaj-art-9a7cc3f1875c49409ea5746ee2e0a330 |
| institution | Kabale University |
| issn | 2352-3964 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj-art-9a7cc3f1875c49409ea5746ee2e0a3302025-08-20T03:38:26ZengElsevierEBioMedicine2352-39642025-08-0111810582810.1016/j.ebiom.2025.105828A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in contextMaxwell R. Lloyd0Rosario Chica-Parrado1Caroline M. Weipert2Todd C. Knepper3Emily L. Podany4Fabiana Napolitano5Dan Ye6Chang-Ching Lin7Yasuaki Uemoto8Jiemin Liao9Claire Wegrzyn10Christine M. Walko11Lianne Y. Ryan12Jennifer C. Keenan13Arielle J. Medford14Shiyuan A. Liu15Gerburg M. Wulf16Katherine K. Clifton17Cynthia X. Ma18Hyo S. Han19Nicole Zhang20Leif W. Ellisen21Aditya Bardia22Carlos L. Arteaga23Ariella B. Hanker24Seth A. Wander25Beth Israel Deaconess Medical Center, Boston, MA, USAUT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USAGuardant Health, Inc., Palo Alto, CA, USAMoffitt Cancer Center, Tampa, FL, USAWashington University in St. Louis, St. Louis, MO, USAUT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USAUT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USAUT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USAUT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USAGuardant Health, Inc., Palo Alto, CA, USAMassachusetts College of Pharmacy and Health Sciences, Boston, MA, USAMoffitt Cancer Center, Tampa, FL, USAMassachusetts General Hospital Cancer Center, Boston, MA, USAMassachusetts General Hospital Cancer Center, Boston, MA, USAMassachusetts General Hospital Cancer Center, Boston, MA, USAWashington University in St. Louis, St. Louis, MO, USABeth Israel Deaconess Medical Center, Boston, MA, USAWashington University in St. Louis, St. Louis, MO, USAWashington University in St. Louis, St. Louis, MO, USAMoffitt Cancer Center, Tampa, FL, USAGuardant Health, Inc., Palo Alto, CA, USAMassachusetts General Hospital Cancer Center, Boston, MA, USAUCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, USAUT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USAUT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USA; Corresponding author. 5323 Harry Hines Blvd., Dallas, TX, 75390, USA.Massachusetts General Hospital Cancer Center, Boston, MA, USA; Corresponding author. 55 Fruit St., Yawkey 9A, Boston, MA, 02114, USA.Summary: Background: CDK4/6 inhibitors (CDK4/6i) are used for management of hormone receptor-positive (HR+) metastatic breast cancer (MBC), and activation of the RAS/MAPK and PI3K/AKT signalling pathways has been implicated in resistance to these agents. Pathogenic NF1 mutations (pNF1m) dysregulate RAS signalling, but NF1 has not been linked to CDK4/6i resistance. We analysed multi-institutional data, real-world evidence, and preclinical models to characterise the impact of pNF1m on CDK4/6i sensitivity. Methods: A retrospective cohort of patients with pNF1m tumours were identified from 4 institutions between 2/2015–5/2023 and evaluated for progression-free survival and intrinsic/acquired resistance on CDK4/6i. Real-world clinical-genomic data from GuardantINFORM between 6/2014 and 3/2023 was analysed for associations between pNF1m and time-to-next-treatment or overall survival following CDK4/6i, adjusted using propensity score weighting. We used CRISPR/Cas9 to delete NF1 in MCF7 and T47D breast cancer cells in vitro. NF1-knockout (NF1-KO) and -wild-type (WT) cells were analysed with respect to CDK4/6i sensitivity, MAPK and PI3K pathway activation, and sensitivity to MAPK and PI3K pathway inhibitors. In parallel, we assessed treatment response in a patient-derived organoid (PDO) harbouring NF1 loss, established from an HR+/HER2− breast tumor following progression on a CDK4/6i. Findings: Among 1962 multicentre patients, we identified 38 with HR+/HER2- MBC, pNF1m, and exposure to CDK4/6i. NF1-associated intrinsic or acquired resistance to CDK4/6i was observed in a majority of tumours, and in those with baseline pNF1m on first-line CDK4/6i, a median progression-free survival of 6.2 months was much less than expected in routine practice. Real-world weighted analysis of 1161 patients comparing 28 pNF1m to 1133 NF1 non-altered tumours demonstrated shorter time-to-next-treatment on CDK4/6i regimens (4.2 vs. 12.4 months, hazard ratio 3.14, 95% confidence interval 2.01–4.93) and overall survival (15.8 vs. 45.2 months, hazard ratio 2.04, 95% confidence interval 1.09–3.82). NF1-deleted cells exhibited reduced sensitivity to CDK4/6i with or without oestrogen suppression, which was accompanied by induction of both MAPK and PI3K pathways, the latter of which was exacerbated by CDK4/6i. Blockade of RAS or AKT, but not MEK or ERK, reversed CDK4/6i resistance mediated by NF1 loss in cell lines and the PDO. Interpretation: NF1 mutations are associated with shorter therapy duration on CDK4/6i in MBC. A causal link between NF1 loss and CDK4/6i resistance was supported by experiments in HR + breast cancer cells. NF1 deletion was accompanied by activation of ERK and AKT, and blockade of RAS or AKT combined with CDK4/6i was effective in NF1-deleted cells and an NF1-mutant PDO. Funding: Breast Cancer Research Foundation DRC-20-001, National Cancer Institute R01CA273246, National Institute of Health P30 CA142543, Susan G. Komen Breast Cancer Foundation SAB1800010, Department of Defence BC 210406, Mary Kay Ash Foundation International Postdoctoral Scholars in Cancer Research Fellowship.http://www.sciencedirect.com/science/article/pii/S2352396425002725HR+ breast cancerMetastatic breast cancerNF1 mutationCDK4/6 inhibitorPrecision medicineResistance mechanisms |
| spellingShingle | Maxwell R. Lloyd Rosario Chica-Parrado Caroline M. Weipert Todd C. Knepper Emily L. Podany Fabiana Napolitano Dan Ye Chang-Ching Lin Yasuaki Uemoto Jiemin Liao Claire Wegrzyn Christine M. Walko Lianne Y. Ryan Jennifer C. Keenan Arielle J. Medford Shiyuan A. Liu Gerburg M. Wulf Katherine K. Clifton Cynthia X. Ma Hyo S. Han Nicole Zhang Leif W. Ellisen Aditya Bardia Carlos L. Arteaga Ariella B. Hanker Seth A. Wander A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context EBioMedicine HR+ breast cancer Metastatic breast cancer NF1 mutation CDK4/6 inhibitor Precision medicine Resistance mechanisms |
| title | A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context |
| title_full | A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context |
| title_fullStr | A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context |
| title_full_unstemmed | A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context |
| title_short | A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context |
| title_sort | bedside to bench translational analysis of nf1 alterations and cdk4 6 inhibitor resistance in hormone receptor positive metastatic breast cancerresearch in context |
| topic | HR+ breast cancer Metastatic breast cancer NF1 mutation CDK4/6 inhibitor Precision medicine Resistance mechanisms |
| url | http://www.sciencedirect.com/science/article/pii/S2352396425002725 |
| work_keys_str_mv | AT maxwellrlloyd abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT rosariochicaparrado abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT carolinemweipert abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT toddcknepper abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT emilylpodany abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT fabiananapolitano abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT danye abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT changchinglin abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT yasuakiuemoto abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT jieminliao abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT clairewegrzyn abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT christinemwalko abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT lianneyryan abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT jenniferckeenan abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT ariellejmedford abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT shiyuanaliu abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT gerburgmwulf abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT katherinekclifton abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT cynthiaxma abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT hyoshan abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT nicolezhang abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT leifwellisen abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT adityabardia abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT carloslarteaga abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT ariellabhanker abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT sethawander abedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT maxwellrlloyd bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT rosariochicaparrado bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT carolinemweipert bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT toddcknepper bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT emilylpodany bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT fabiananapolitano bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT danye bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT changchinglin bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT yasuakiuemoto bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT jieminliao bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT clairewegrzyn bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT christinemwalko bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT lianneyryan bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT jenniferckeenan bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT ariellejmedford bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT shiyuanaliu bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT gerburgmwulf bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT katherinekclifton bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT cynthiaxma bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT hyoshan bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT nicolezhang bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT leifwellisen bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT adityabardia bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT carloslarteaga bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT ariellabhanker bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext AT sethawander bedsidetobenchtranslationalanalysisofnf1alterationsandcdk46inhibitorresistanceinhormonereceptorpositivemetastaticbreastcancerresearchincontext |